NCT00599469

Brief Summary

Alzheimer's disease is a progressive and fatal brain disease. This study will investigate the use of far infrared radiation treatment for the disease.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
4

participants targeted

Target at below P25 for phase_1 alzheimer-disease

Timeline
Completed

Started Feb 2008

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 11, 2008

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 23, 2008

Completed
9 days until next milestone

Study Start

First participant enrolled

February 1, 2008

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2009

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2009

Completed
Last Updated

August 17, 2009

Status Verified

August 1, 2009

Enrollment Period

1.1 years

First QC Date

January 11, 2008

Last Update Submit

August 14, 2009

Conditions

Alzheimer Disease

Keywords

Acute Confusional Senile DementiaAlzheimer Type Senile DementiaSENILE PLAQUESNEUROFIBRILLARY TANGLESNEUROPIL THREADS

Outcome Measures

Primary Outcomes (1)

  • Management and Cure of Alzheimer's Disease

    1 year

Secondary Outcomes (1)

  • Management and Cure of Dementia

    1 year

Study Arms (1)

1

OTHER

Far Infrared Radiation

Radiation: Far Infrared Radiation (5μm to 20μm wavelength)

Interventions

Far Infrared Radiation (5μm to 20μm wavelength)RADIATION

Far Infrared radiation for 30 to 40 minutes per treatment session.

1

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • People with Alzheimer's disease

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Centre for Incurable Diseases

Toronto, Ontario, M4V 1L5, Canada

Location

MeSH Terms

Conditions

Alzheimer DiseasePlaque, Amyloid

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Ken Nedd, M.D.

    GAAD Medical Research Institute Inc.

    PRINCIPAL INVESTIGATOR

  • Kwasi Donyina, Ph.D.

    GAAD Medical Research Institute Inc.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 11, 2008

First Posted

January 23, 2008

Study Start

February 1, 2008

Primary Completion

March 1, 2009

Study Completion

April 1, 2009

Last Updated

August 17, 2009

Record last verified: 2009-08

Locations

CA(1)